Faculty profile

Danielle Charpentier

Back to faculty

ProfessorDépartement de médecineUniversité de Montréal

Signals and details

Research

Read how they describe their research on their Université de Montréal profile.

Latest papers

Phase 1/2 Trial of Durvalumab Plus Tremelimumab and Stereotactic Body Radiation Therapy for Metastatic Head and Neck Carcinoma.
International journal of radiation oncology, biology, physics · 2026
Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma.
Oral oncology · 2024
Predictors of prolonged treatment time intervals in oral cavity cancer.
Oral oncology · 2023

All 18 publications

Latest funding

Milléniaux, survivance au cancer et besoins d'apprentissage: journée d'échange entre des jeunes adultes survivant au cancer, des cliniciens, des représentants communautaires et des chercheurs
CIHR · 2018 · Co-investigator
$9,940
Le Patient Accompagnateur, une Ressource Organisationnelle comme Levier pour une Expérience patient améliorée en oncologie (PAROLE-Onco)
CIHR · 2017 · Co-investigator
$1,000,000

All 2 grants and awards

18 publications.

Phase 1/2 Trial of Durvalumab Plus Tremelimumab and Stereotactic Body Radiation Therapy for Metastatic Head and Neck Carcinoma.

Bahig H, Ye RZ, Aubin F, Nguyen-Tan PF, Soulieres D, Debenham BJ, Charpentier D, Palma DA, Chua N, Winquist E, Jamal R, Sultanem K, Ballivy O, Filion E, Mathew J, Maganti M, Wong P

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2026.07.052 PMID: 42586218

Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma.

Hes C, Desilets A, Tonneau M, El Ouarzadi O, De Figueiredo Sousa M, Bahig H, Filion É, Nguyen-Tan PF, Christopoulos A, Benlaïfaoui M, Derosa L, Alves Costa Silva C, Ponce M, Malo J, Belkad W, Charpentier D, Aubin F, Hamilou Z, Jamal R, Messaoudene M, Soulières D, Routy B

Oral oncology202420 citationsOpen Access

DOI: 10.1016/j.oraloncology.2023.106623 PMID: 38006691

Predictors of prolonged treatment time intervals in oral cavity cancer.

Dayan G, Bahig H, Fortin B, Filion É, Nguyen-Tan PF, O'Sullivan B, Charpentier D, Soulières D, Gologan O, Nelson K, Létourneau L, Schmittbuhl M, Ayad T, Bissada E, Guertin L, Tabet P, Christopoulos A

Oral oncology20238 citationsOpen Access

DOI: 10.1016/j.oraloncology.2023.106622 PMID: 37948896

Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress.

Desilets A, McCarvill W, Aubin F, Bahig H, Ballivy O, Charpentier D, Filion É, Jamal R, Lambert L, Nguyen-Tan PF, Vadnais C, Weng X, Soulières D

Current oncology (Toronto, Ont.)20229 citationsOpen Access

DOI: 10.3390/curroncol29020045 PMID: 35200545

The Experiential Learning Pathway of Cancer Survivors as They Recover Their Lives Post-Treatment: A Qualitative Study.

Bilodeau K, Henriksen C, Lee V, Vachon MF, Charpentier D, Folch N, Pepin J, Pomey MP, Piché L, Fernandez N

Global qualitative nursing research20229 citationsOpen Access

DOI: 10.1177/23333936221083026 PMID: 35572366

COVID-19 Impact on Diagnosis and Staging of Colorectal Cancer: A Single Tertiary Canadian Oncology Center Experience.

Castonguay M, El Sayed R, Richard C, Vachon MF, Nassabein R, Charpentier D, Tehfé M

Current oncology (Toronto, Ont.)2022

DOI: 10.3390/curroncol29050268 PMID: 35621658

Learning through the experience of cancer survivorship: differences across age groups.

Bilodeau K, Lee V, Pepin J, Pomey MP, Sultan S, Folch N, Charpentier D, Vachon MF, Dumont-Lagacé É, Piché L

Journal of psychosocial oncology202111 citations

DOI: 10.1080/07347332.2021.1878316 PMID: 33527878

From theory to practice: implementing a standardized, interactive education session on oral anticancer medication (OAM) for patients and their caregivers.

Chouinard A, Charpentier D, Doucet S, Messier C, Vachon MF

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2020

DOI: 10.1007/s00520-019-05236-8 PMID: 31848704

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.

Bahig H, Aubin F, Stagg J, Gologan O, Ballivy O, Bissada E, Nguyen-Tan FP, Soulières D, Guertin L, Filion E, Christopoulos A, Lambert L, Tehfe M, Ayad T, Charpentier D, Jamal R, Wong P

BMC cancer201961 citationsOpen Access

DOI: 10.1186/s12885-019-5266-4 PMID: 30642290

A case of eribulin mesylate and demyelinating polyneuropathy with myokymic discharges.

Peyronnard C, Charpentier D, Botez SA

Muscle & nerve2016

DOI: 10.1002/mus.24890 PMID: 26332614

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Danielle Charpentier

Research

Latest papers

Latest funding

Phase 1/2 Trial of Durvalumab Plus Tremelimumab and Stereotactic Body Radiation Therapy for Metastatic Head and Neck Carcinoma.

Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma.

Predictors of prolonged treatment time intervals in oral cavity cancer.

Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress.

The Experiential Learning Pathway of Cancer Survivors as They Recover Their Lives Post-Treatment: A Qualitative Study.

COVID-19 Impact on Diagnosis and Staging of Colorectal Cancer: A Single Tertiary Canadian Oncology Center Experience.

Learning through the experience of cancer survivorship: differences across age groups.

From theory to practice: implementing a standardized, interactive education session on oral anticancer medication (OAM) for patients and their caregivers.

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.

A case of eribulin mesylate and demyelinating polyneuropathy with myokymic discharges.

Milléniaux, survivance au cancer et besoins d'apprentissage: journée d'échange entre des jeunes adultes survivant au cancer, des cliniciens, des représentants communautaires et des chercheurs

Le Patient Accompagnateur, une Ressource Organisationnelle comme Levier pour une Expérience patient améliorée en oncologie (PAROLE-Onco)

Frequent collaborators

Houda Bahig

Francine Aubin

Louise Lambert

Tareck Ayad

Jacinthe Pepin

Olivier Ballivy

Édith Filion

Denis Soulières

Karine Bilodeau

Marie-Pascale Pomey

Matthieu Schmittbuhl

Mustapha Tehfe

Serge Sultan

Maroie Barkati

Manon Bélair

Levon Igidbashian

Jean-Pierre Ayoub

Eric Winquist

Philip Wong

Lori Wood

Brian O'Sullivan

Bertrand Routy

Nicolas Fernandez